Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 20 01 2022
revised: 06 02 2022
accepted: 07 02 2022
entrez: 27 2 2022
pubmed: 28 2 2022
medline: 8 3 2022
Statut: ppublish

Résumé

Due to some interconnectedness at the molecular level, this study assessed the possible influence of laboratory parameters associated with systemic inflammatory environment on programmed death-ligand 1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC). We assessed effects of c-reactive protein (CRP), albumin, haemoglobin, neutrophil, and lymphocyte levels on PD-L1 expression in NSCLC. Patient data were obtained retrospectively from LUCAS, the Czech registry of patients with lung carcinomas. Correlations of two continuous parameters (PD-L1 expression and laboratory parameters) were analysed by correlation coefficient. Differences in continuous parameters between two or more groups were tested by Mann-Whitney or Kruskal-Wallis tests. Independence of two categorical parameters was tested by chi-square test. We demonstrated no influence of the investigated laboratory parameters on PD-L1 expression in NSCLC, either in continuous or categorical division of variables. Inflammatory laboratory parameters at time of NSCLC diagnosis are unlikely to affect the determination of PD-L1 expression.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Due to some interconnectedness at the molecular level, this study assessed the possible influence of laboratory parameters associated with systemic inflammatory environment on programmed death-ligand 1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC).
PATIENTS AND METHODS METHODS
We assessed effects of c-reactive protein (CRP), albumin, haemoglobin, neutrophil, and lymphocyte levels on PD-L1 expression in NSCLC. Patient data were obtained retrospectively from LUCAS, the Czech registry of patients with lung carcinomas. Correlations of two continuous parameters (PD-L1 expression and laboratory parameters) were analysed by correlation coefficient. Differences in continuous parameters between two or more groups were tested by Mann-Whitney or Kruskal-Wallis tests. Independence of two categorical parameters was tested by chi-square test.
RESULTS RESULTS
We demonstrated no influence of the investigated laboratory parameters on PD-L1 expression in NSCLC, either in continuous or categorical division of variables.
CONCLUSION CONCLUSIONS
Inflammatory laboratory parameters at time of NSCLC diagnosis are unlikely to affect the determination of PD-L1 expression.

Identifiants

pubmed: 35220253
pii: 42/3/1563
doi: 10.21873/anticanres.15630
doi:

Substances chimiques

ALB protein, human 0
B7-H1 Antigen 0
Biomarkers, Tumor 0
CD274 protein, human 0
Hemoglobins 0
C-Reactive Protein 9007-41-4
Serum Albumin, Human ZIF514RVZR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1563-1569

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Martin Svaton (M)

Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic svatonm@fnplzen.cz.

Marie Drosslerova (M)

Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic.

Ondrej Fischer (O)

Department of Respiratory Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.

Miloslav Marel (M)

Department of Pneumology, 2 Faculty of Medicine, Charles University, Prague, Czech Republic.

Michal Hrnciarik (M)

Department of Pneumology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.

Ondrej Venclicek (O)

Department of Respiratory Diseases, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic.

Petr Zuna (P)

Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic.

Michal Svoboda (M)

Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.

Jiri Blazek (J)

Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Monika Bratova (M)

Department of Respiratory Diseases, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic.

Andrea Mullerova (A)

Department of Respiratory Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.

Bohuslava Vankova (B)

Department of Pathology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Daniel Krejci (D)

Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH